SITAJAN MET 50/1000 Tablet is a fixed-dose oral medication combining two well-established antidiabetic agents: Sitagliptin, a DPP-4 inhibitor, and Metformin Hydrochloride, a biguanide. This combination is formulated to provide enhanced glycemic control in adult patients with type 2 diabetes mellitus, particularly in those who are inadequately managed with Metformin monotherapy or require additional glucose-lowering support.

Sitagliptin 50 mg functions by inhibiting the DPP-4 enzyme, thereby increasing the levels of active incretin hormones in the bloodstream. These hormones stimulate insulin secretion in a glucose-dependent manner and suppress glucagon production following meals, effectively lowering postprandial blood glucose levels. Sitagliptin is favored for its weight-neutral profile and low risk of hypoglycemia, making it a suitable choice for long-term diabetes management.

Metformin Hydrochloride 1000 mg complements Sitagliptin by decreasing hepatic glucose production and improving insulin sensitivity in peripheral tissues. As the most commonly prescribed first-line therapy for type 2 diabetes, Metformin remains a cornerstone of diabetes care, particularly for overweight patients, due to its beneficial effects on weight and cardiovascular outcomes.

The combination of Sitagliptin and a higher dose of Metformin in SITAJAN MET 50/1000 offers potent glycemic control and is typically recommended for patients requiring a stronger pharmacological intervention. The tablet is generally taken once or twice daily with food to enhance tolerability and reduce gastrointestinal side effects associated with Metformin.

SITAJAN MET 50/1000 is manufactured by Bluepill Express, a trusted name in third-party pharmaceutical production. The formulation is developed in compliance with WHO-GMP, ISO 9001, and other international manufacturing standards. Every batch undergoes a stringent quality assurance protocol, including raw material analysis, in-process validation, and final quality control testing, ensuring the product’s purity, efficacy, and safety.

The production infrastructure includes high-speed compression machines, validated coating systems, and automated packaging lines. Tablets are available in various customized packaging options such as alu-alu or blister packs, tailored to meet the needs of global distributors, importers, and marketing authorization holders.

Bluepill Express also provides comprehensive regulatory documentation support including Certificate of Analysis (COA), Certificate of Pharmaceutical Product (COPP), Stability Data, Product Dossier (CTD/ACTD), and other relevant certifications for international export and tenders.

SITAJAN MET 50/1000 Tablet is widely used across Asia, Africa, the Middle East, CIS countries, and Latin America. It plays a critical role in diabetes treatment regimens, often prescribed as part of a dual therapy approach for better long-term glucose control and reduction of diabetes-related complications.

This formulation is suitable for diabetic patients who require a higher Metformin dose to achieve desired therapeutic goals without switching to insulin or other injectable therapies. It simplifies treatment by combining two effective agents into a single, easy-to-administer tablet, thereby enhancing patient adherence and convenience.